About US
Contact us
-
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbusterWhen Amgen signed an outcomes-based reimbursement deal for its blockbuster rheumatoid arthritis drug Enbrel with Harvard Pilgrim Healthcare in 2017, it seemed like a strategy for preserving the marke2019/12/4
-
Pelosi pricing plan will yield 100 fewer new drugs, White House predictsAs debate over drug pricing proposals rolls on in Washington, White House advisers have concludedHouse Speaker Nancy Pelosi's aggressive pricing plan would result in 100 fewer new drugs over a decade2019/12/3
-
Merck, insurers fight over $1.3B in damages from cyberattack: BloombergWhen Merck first confirmed a cyberattack hit the company back in June 2017, it was impossible to know the extent of the damage or what would come from the attack. But those details are a little clear2019/12/3
-
AstraZeneca offloads more Seroquel rights, this time to Cheplapharm for $42MAstraZeneca has been hiving off drug rights left and right in recent years as a quick—but controversial—way to generate cash. With billions in rights sales already in its pocket, the company Tuesdayo2019/12/2
-
Blockbuster in the balance: Celgene's Reblozyl faces FDA committee for myelodysplastic syndromesIn its final days as an independent company, Celgene scored a win last month with the FDA's approval of rare blood disease med Reblozyl––a potential blockbuster in some analysts' eyes. Now, the FDA w2019/12/2
-
Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study saysA few days after an 11-year-old boy in Japan was diagnosed with the H3N2 strain of the flu and prescribed Xofluza from Roche’s Genentech, he stopped responding to the drug. Then his sister came down2019/11/29
-
Acadia's Nuplazid rebounds in schizophrenia with study winAcadia's Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn't Nuplazid's last go at the indication, and now a phase2019/11/29
-
ICER gets on board with AbbVie's Rinvoq for RA but frets over 'fair pricing' of next-gen drugsWhen the Institute for Clinical and Economic Review (ICER) first released its draft report on the cost effectiveness of next-generation JAK inhibitors to treat rheumatoid arthritis, it blasted all th2019/11/28
-
Teva, others talk settlements with feds in yearslong generics price fixing probe: reportFederal prosecutors have been probing alleged generics price fixing for years, and, over the summer, lawmakers urged them to get moving with the investigation. Now, Teva and otherdrugmakersare in tal2019/11/28
-
Global Blood Therapeutics scores blockbuster FDA nod for Oxbryta, forecasts 'paradigm shift' in sickle cell diseaseAnother day, another early FDA nod. Global Blood Therapeutics has its first drug approval, and it’s one that’ll bring a “paradigm shift” in how patients with sickle cell disease are treated, execs sa2019/11/27